Research Paper Volume 12, Issue 9 pp 8565—8582

Implications of maraviroc and/or rapamycin in a mouse model of fragility

Figure 6. Analyses of the molecular pathways involved in the mechanism of action of RAPA and MVC (A) Western blot analysis of the protein levels of AKT (phosphorylated and total), NF-kb (phosphorylated and total), mTOR, AMPK (phosphorylated and total), Caspase 3, SIRT1, SIRT3, SIRT6, IRS1, IRS2 and GAPDH as endogenous control, in mice treated or not with maraviroc (MVC group), Rapamycin (RAPA group) or combination of both (MVC-RAPA group). (B) Relative quantification of the protein levels in (A) relative to GAPDH control. (C) Box plots showing the average protein levels from (B). Data were analyzed using Student t test´s. *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001.